BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35858237)

  • 1. Risk factors and prognostic significance of postoperative complications following lateral pelvic lymph node dissection for rectal cancer: results of the multicenter lateral node study in China.
    Zhou S; Tang J; Mei S; Lou Z; Fu W; Feng B; Yang Y; Sun Y; Liu Q;
    Jpn J Clin Oncol; 2022 Oct; 52(10):1150-1158. PubMed ID: 35858237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of lateral pelvic lymph node dissection for middle-low rectal cancer patients with lateral pelvic lymph node metastasis: a propensity score matching study.
    Zhou S; Jiang Y; Pei W; Liang J; Zhou Z
    BMC Cancer; 2022 Feb; 22(1):136. PubMed ID: 35109810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis.
    Zhou S; Jiang Y; Pei W; Liang J; Zhou Z
    BMC Surg; 2021 Dec; 21(1):441. PubMed ID: 34961494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesorectal excision with lateral lymph node dissection for mid-low rectal cancer with lateral lymph node metastasis: efficacy and prognostic analysis.
    Zhou S; Jiang Y; Liang J; Liu Q
    World J Surg Oncol; 2022 Mar; 20(1):97. PubMed ID: 35351137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short- and long-term outcomes of laparoscopic versus open selective lateral pelvic lymph node dissection for locally advanced middle-low rectal cancer: Results of a multicentre lateral node study in China.
    Tang J; Zhou S; Zhao W; Lou Z; Liang J; Feng B; Yang Y; Wang X; Liu Q;
    Colorectal Dis; 2022 Nov; 24(11):1325-1334. PubMed ID: 35713974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of indocyanine green-enhanced near-infrared fluorescence-guided imaging in laparoscopic lateral pelvic lymph node dissection for middle-low rectal cancer.
    Zhou SC; Tian YT; Wang XW; Zhao CD; Ma S; Jiang J; Li EN; Zhou HT; Liu Q; Liang JW; Zhou ZX; Wang XS
    World J Gastroenterol; 2019 Aug; 25(31):4502-4511. PubMed ID: 31496628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Selective Lateral Node Dissection Based on Magnetic Resonance Imaging in Rectal Cancer After Preoperative Chemoradiotherapy.
    Park BK; Lee SJ; Hur BY; Kim MJ; Chan Park S; Chang HJ; Kim DY; Oh JH
    J Surg Res; 2018 Dec; 232():227-233. PubMed ID: 30463722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Lateral Pelvic Node Dissection on the Survival of Patients in Low Rectal Cancer Subgroups Based on Lymph Node Size.
    Hida K; Nishizaki D; Sumii A; Okamura R; Sakai Y; Konishi T; Akagi T; Yamaguchi T; Akiyoshi T; Fukuda M; Yamamoto S; Arizono S; Uemura M; Hasegawa H; Kawada K; Morita S; Watanabe M;
    Ann Surg Oncol; 2021 Oct; 28(11):6179-6188. PubMed ID: 34255243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective dissecting range and prognostic significance of lateral pelvic lymph node dissection for middle-low rectal cancer patients with lateral pelvic lymph node metastasis: Results of a large multicenter lateral node collaborative group in China.
    Zhou S; Tang J; Liang J; Lou Z; Fu W; Feng B; Yang Y; Xiao Y; Liu Q
    Front Oncol; 2022; 12():916285. PubMed ID: 36033473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
    Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
    Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary experience with lateral pelvic lymph node dissection in locally advanced rectal cancer.
    Sinukumar S; Engineer R; Saklani A
    Indian J Gastroenterol; 2015 Jul; 34(4):320-4. PubMed ID: 26334237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiotherapy followed by lateral pelvic lymph node dissection for rectal cancer patients: A retrospective study of its safety and indications.
    Zhou S; Jiang Y; Pei W; Zhou H; Liang J; Zhou Z
    J Surg Oncol; 2021 Sep; 124(3):354-360. PubMed ID: 33882149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and safety of lateral pelvic lymph node dissection for elderly patients with middle-low rectal cancer: results of a large multicenter lateral node collaborative group study in China.
    Zhou S; Mei S; Feng B; Yang Y; Wang X; Wang Q; Liu Q
    Tech Coloproctol; 2023 Aug; 27(8):655-664. PubMed ID: 36515808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can neoadjuvant chemoradiotherapy before lateral pelvic lymph node dissection improve local control and prognosis in rectal cancer patients with clinically suspected lateral lymph node metastasis? A multicenter lateral node study in China.
    Xie Z; Chen Q; Feng B; Jiang Y; Wang X; Xing W; Liu Q;
    BMC Cancer; 2024 Jan; 24(1):115. PubMed ID: 38263067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of survival and functional outcomes after total mesorectal excision with or without lateral pelvic lymph node dissection in rectal cancer surgery.
    Hajibandeh S; Hajibandeh S; Matthews J; Palmer L; Maw A
    Surgery; 2020 Sep; 168(3):486-496. PubMed ID: 32620303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating predictive factors for determining the presence of lateral pelvic node metastasis in rectal cancer patients following neoadjuvant chemoradiotherapy.
    Wang P; Zhou S; Zhou H; Liang J; Zhou Z
    Colorectal Dis; 2019 Jul; 21(7):791-796. PubMed ID: 30801862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of and risk factors for lymphocele formation after lateral pelvic lymph node dissection for rectal cancer: a retrospective study.
    Ochiai K; Kaneko M; Nozawa H; Kawai K; Hata K; Tanaka T; Nishikawa T; Shuno Y; Sasaki K; Hiyoshi M; Emoto S; Murono K; Sonoda H; Ishihara S
    Colorectal Dis; 2020 Feb; 22(2):161-169. PubMed ID: 31454448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncological Outcomes of Patients with Locally Advanced Rectal Cancer and Lateral Pelvic Lymph Node Involvement.
    Sapci I; Delaney CP; Liska D; Amarnath S; Kalady MF; Steele SR; Gorgun E
    J Gastrointest Surg; 2019 Jul; 23(7):1454-1460. PubMed ID: 31012043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
    Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
    World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.
    Oh HK; Kang SB; Lee SM; Lee SY; Ihn MH; Kim DW; Park JH; Kim YH; Lee KH; Kim JS; Kim JW; Kim JH; Chang TY; Park SC; Sohn DK; Oh JH; Park JW; Ryoo SB; Jeong SY; Park KJ
    Ann Surg Oncol; 2014 Jul; 21(7):2280-7. PubMed ID: 24604580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.